Literature DB >> 21910367

Treatment of Crohn's disease with cannabis: an observational study.

Timna Naftali1, Lihi Bar Lev, Doron Yablecovitch, Doron Yablekovitz, Elisabeth Half, Fred M Konikoff.   

Abstract

BACKGROUND: The marijuana plant cannabis is known to have therapeutic effects, including improvement of inflammatory processes. However, no report of patients using cannabis for Crohn's disease (CD) was ever published.
OBJECTIVES: To describe the effects of cannabis use in patients suffering from CD.
METHODS: In this retrospective observational study we examined disease activity, use of medication, need for surgery, and hospitalization before and after cannabis use in 30 patients (26 males) with CD. Disease activity was assessed by the Harvey Bradshaw index for Crohn's disease.
RESULTS: Of the 30 patients 21 improved significantly after treatment with cannabis. The average Harvey Bradshaw index improved from 14 +/- 6.7 to 7 +/- 4.7 (P < 0.001). The need for other medication was significantly reduced. Fifteen of the patients had 19 surgeries during an average period of 9 years before cannabis use, but only 2 required surgery during an average period of 3 years of cannabis use.
CONCLUSIONS: This is the first report of cannabis use in Crohn's disease in humans. The results indicate that cannabis may have a positive effect on disease activity, as reflected by reduction in disease activity index and in the need for other drugs and surgery. Prospective placebo-controlled studies are warranted to fully evaluate the efficacy and side effects of cannabis in CD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21910367

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  45 in total

Review 1.  Complementary Therapies in Inflammatory Bowel Diseases.

Authors:  Henit Yanai; Nir Salomon; Adi Lahat
Journal:  Curr Gastroenterol Rep       Date:  2016-12

Review 2.  Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches.

Authors:  Abigail R Basson; Minh Lam; Fabio Cominelli
Journal:  Gastroenterol Clin North Am       Date:  2017-12       Impact factor: 3.806

3.  Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial.

Authors:  Timna Naftali; Refael Mechulam; Amir Marii; Gila Gabay; Asaf Stein; Miriam Bronshtain; Ido Laish; Fabiana Benjaminov; Fred M Konikoff
Journal:  Dig Dis Sci       Date:  2017-03-27       Impact factor: 3.199

Review 4.  Drug-Herb Interactions in the Elderly Patient with IBD: a Growing Concern.

Authors:  Haider Rahman; Marina Kim; Galen Leung; Jesse A Green; Seymour Katz
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

5.  Profiles of Patients Who Use Marijuana for Inflammatory Bowel Disease.

Authors:  Ann Marie Kerlin; Millie Long; Michael Kappelman; Christopher Martin; Robert S Sandler
Journal:  Dig Dis Sci       Date:  2018-03-29       Impact factor: 3.199

6.  Rapid identification of drug-type strains in Cannabis sativa using loop-mediated isothermal amplification assay.

Authors:  Masashi Kitamura; Masako Aragane; Kou Nakamura; Kazuhito Watanabe; Yohei Sasaki
Journal:  J Nat Med       Date:  2016-08-17       Impact factor: 2.343

7.  Association Between Cannabis Use and Complications Related to Crohn's Disease: A Retrospective Cohort Study.

Authors:  Chimezie Mbachi; Bashar Attar; Yuchen Wang; Isaac Paintsil; Benjamin Mba; Setri Fugar; Rohit Agrawal; Roberto Carlos Simons-Linares; Palash Jaiswal; William Trick; Vikram Kotwal
Journal:  Dig Dis Sci       Date:  2019-03-02       Impact factor: 3.199

Review 8.  The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information.

Authors:  Arun Swaminath; Eric P Berlin; Adam Cheifetz; Ed Hoffenberg; Jami Kinnucan; Laura Wingate; Sarah Buchanan; Nada Zmeter; David T Rubin
Journal:  Inflamm Bowel Dis       Date:  2019-02-21       Impact factor: 5.325

9.  The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.

Authors:  B Romano; F Borrelli; I Fasolino; R Capasso; F Piscitelli; Mg Cascio; Rg Pertwee; D Coppola; L Vassallo; P Orlando; V Di Marzo; Aa Izzo
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

10.  Cannabis Abuse Is Increasing and Associated with Increased Emergency Department Utilization in Gastroenterology Patients.

Authors:  John Gubatan; Kyle Staller; Kenneth Barshop; Braden Kuo
Journal:  Dig Dis Sci       Date:  2016-03-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.